nifekalant hydrochloride has been researched along with mexiletine in 1 studies
| Studies (nifekalant hydrochloride) | Trials (nifekalant hydrochloride) | Recent Studies (post-2010) (nifekalant hydrochloride) | Studies (mexiletine) | Trials (mexiletine) | Recent Studies (post-2010) (mexiletine) |
|---|---|---|---|---|---|
| 138 | 16 | 38 | 1,488 | 210 | 227 |
| Protein | Taxonomy | nifekalant hydrochloride (IC50) | mexiletine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.138 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 10 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 3 | |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | 2.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, LT; Iinuma, H; Sagara, K; Sahara, M; Watanabe, H; Yamashita, T | 1 |
1 other study(ies) available for nifekalant hydrochloride and mexiletine
| Article | Year |
|---|---|
Nifekalant hydrochloride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patient undergoing coronary artery bypass grafting and the Dor approach.
Topics: Aged; Anti-Arrhythmia Agents; Coronary Artery Bypass; Drug Resistance; Electric Countershock; Electrocardiography; Humans; Lidocaine; Male; Mexiletine; Potassium Channel Blockers; Pyrimidinones; Tachycardia, Ventricular | 2003 |